IDEXX Laboratories, Inc. (IDXX): Price and Financial Metrics
IDEXX Laboratories, Inc. (IDXX)
Today's Latest Price: $429.66 USD
Updated Oct 23 4:00pm
Add IDXX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
IDXX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IDXX is 9.07 -- better than 96.36% of US stocks.
- With a one year PEG ratio of 654.72, Idexx Laboratories Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.62% of US stocks.
- The price/operating cash flow metric for Idexx Laboratories Inc is higher than 94.82% of stocks in our set with a positive cash flow.
- If you're looking for stocks that are quantitatively similar to Idexx Laboratories Inc, a group of peers worth examining would be CLX, EBAY, ROK, BBY, and CVNA.
- IDXX's SEC filings can be seen here. And to visit Idexx Laboratories Inc's official web site, go to www.idexx.com.
IDXX Stock Price Chart Interactive Chart >
IDXX Price/Volume Stats
| Current price | $429.66 | 52-week high | $431.15 |
| Prev. close | $423.59 | 52-week low | $168.65 |
| Day low | $423.55 | Volume | 227,300 |
| Day high | $429.73 | Avg. volume | 548,279 |
| 50-day MA | $388.10 | Dividend yield | N/A |
| 200-day MA | $317.13 | Market Cap | 36.54B |
IDEXX Laboratories, Inc. (IDXX) Company Bio
IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.
IDXX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $429.66 | $63.53 | -85% |
We started the process of determining a valid price forecast for Idexx Laboratories Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Idexx Laboratories Inc ranked in the 14th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for IDXX, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 18.74 -- which is good for besting 83.4% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately merely 10.77% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.78% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -85% |
| 1% | -85% |
| 2% | -85% |
| 3% | -85% |
| 4% | -85% |
| 5% | -84% |
MYGN, LMNX, QGEN, BSX, and ELAN can be thought of as valuation peers to IDXX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...